<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966769</url>
  </required_header>
  <id_info>
    <org_study_id>GICOR -SEOR 5-16</org_study_id>
    <nct_id>NCT02966769</nct_id>
  </id_info>
  <brief_title>N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation</brief_title>
  <official_title>Multicentric Retrospective Observation Study: Neoadjuvant Treatment and Surgery Versus Definitive Chemoradiation in the Non-Small Cell Lung Cancer (NSCLC) IIIA-N2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multicenter retrospective study is to compare overall survival in
      patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus
      definitive chemoradiation.

      Secondary objectives are to analyze disease-free survival, median survival, locoregional and
      distant relapses as well as mortality and toxicity related to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on data published by the Intergroup 0139 trial, induction therapy followed by surgery
      in patients with stage IIIA-N2 NSCLC can increase overall survival compared to exclusive
      radical chemoradiation treatment.

      The major handicap of all studies addressing the role of surgery in IIIA-N2 NSCLC is the
      difficulty of recruiting patients. Therefore, multicenter studies are necessary to confirm
      the hypothesis generated by the INT 0139.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of Relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">294</enrollment>
  <condition>Non-small-Cell Lung Carcinoma</condition>
  <condition>Surgery</condition>
  <condition>Stage IIIA-N2</condition>
  <condition>Chemoradiation</condition>
  <condition>Survival</condition>
  <arm_group>
    <arm_group_label>Chemoradiation Group</arm_group_label>
    <description>Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (&gt;/= 60 Gy) plus Platinum-based Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant treatment plus Surgery Group</arm_group_label>
    <description>Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus &gt;/= 45Gy) followed by Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Overall survival</intervention_name>
    <description>Compare overall survival between both groups.</description>
    <arm_group_label>Chemoradiation Group</arm_group_label>
    <arm_group_label>Neoadjuvant treatment plus Surgery Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage IIIA-N2 NSCLC potentially resectable at diagnosis.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIA (N2) disease

          -  Potentially resectable disease

          -  Stage Lung Cancer with CT scan or PET-CT.

          -  N2 involvement: it is not necessary pathological proof.

          -  No progression after induction treatment.

        Exclusion Criteria:

          -  T4 or N3 stage.

          -  Bulky disease or not resectable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Couñago, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Montemuiño, MDPhd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28290</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</investigator_affiliation>
    <investigator_full_name>Felipe Couñago</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

